MESO Stock Summary and Trading Ideas (Mesoblast Limited - American Depositary Shares | NASDAQ:MESO)

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.

As of May 17, 2024, MESO stock price climbed to $7.35 with 181,263 million shares trading.

MESO has a beta of 2.83, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.06 to the broad based SPY ETF.

MESO has a market cap of $838.42 million. This is considered a Small Cap stock.

Last quarter Mesoblast Limited - American Depositary Shares reported $2 million in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-231,000 and exceeded earnings estimates by $.02.

In the last 3 years, MESO stock traded as high as $17.70 and as low as $1.61.

MESO has underperformed the market in the last year with a price return of -3.8% while the SPY ETF gained +29.1%. However, in the short term, MESO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +263.9% vs +6.3% return in SPY. But in the last 2 weeks, MESO shares have been beat by the market, returning -2.0% compared to an SPY return of +3.6%.

MESO support price is $6.64 and resistance is $7.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO stock will trade within this expected range on the day.